Related Experiment Video
Updated: May 21, 2026
Determining the Chemical Composition of Corrosion Inhibitor/Metal Interfaces with XPS: Minimizing Post Immersion Oxidation
Published on: March 15, 2017
ALK Inhibitors, a Pharmaceutical Perspective
1Department of Cell Biology, Oncology, Nerviano Medical Sciences Milan, Italy.
Abstract:
In 2007, the ALK tyrosine kinase was described as a potential therapeutic target for a subset of non-small-cell lung cancer patients. Clinical proof of concept, culminating in the recent approval by the Food and Drug Administration of the Pfizer drug crizotinib followed in record time. The drug was approved together with a companion diagnostic for detection of patients eligible for therapy. This remarkable example of the coming of age of personalized medicine in cancer therapy is hopefully only an auspice of things to come in a rapidly developing field. Perhaps unsurprisingly, however, the appearance of clinical acquired resistance to crizotinib was observed early on in clinical testing, with the identification of several ALK secondary point mutations which diminish drug efficacy and which open the way for development of second-generation inhibitors. It is also emerging that acquired resistance to crizotinib may additionally occur through ALK-independent mechanisms, which still need to be elucidated in detail. Here we discuss the factors that led to such a rapid approval of a targeted agent, and we describe the second-generation compounds currently in development.
Insights
Crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, offers personalized medicine for non-small-cell lung cancer. Acquired resistance to this targeted therapy emerges through ALK mutations and independent mechanisms, necessitating new treatment strategies.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Anaplastic lymphoma kinase (ALK) identified as a therapeutic target in non-small-cell lung cancer (NSCLC) in 2007.
- Rapid approval of crizotinib, an ALK inhibitor, marked a significant advancement in personalized cancer therapy.
- Development of companion diagnostics for patient selection enabled targeted treatment strategies.
Purpose of the Study:
- To discuss factors contributing to the rapid approval of crizotinib.
- To describe the mechanisms of acquired resistance to crizotinib.
- To review second-generation ALK inhibitors in development.
Main Methods:
- Literature review of ALK inhibitors in NSCLC treatment.
- Analysis of clinical trial data regarding crizotinib efficacy and resistance.
- Exploration of emerging resistance pathways, including ALK-independent mechanisms.
Main Results:
- Crizotinib demonstrated clinical efficacy, leading to FDA approval for ALK-positive NSCLC.
- Acquired resistance to crizotinib has been observed, primarily due to secondary ALK point mutations.
- ALK-independent resistance mechanisms are also emerging and require further elucidation.
Conclusions:
- The rapid development and approval of crizotinib exemplify personalized medicine in oncology.
- Understanding resistance mechanisms is crucial for developing next-generation therapies.
- Continued research into ALK-independent resistance pathways is essential for overcoming treatment limitations.
Related Concept Videos
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:24Principles of Drug Action
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:30Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
01:26Pharmaceutical Poisoning: Treatment Strategies
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...